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ABSTRACT
MicroRNAs (miRNAs) regulate posttranscriptional gene expression usually by binding to 3’-untranslated regions (3’-UTRs) of target
message RNAs (mRNAs). Hence genetic polymorphisms on 3’-UTRs of mRNAs may alter binding affinity between miRNAs target 3’-UTRs,
thereby altering translational regulation of target mRNAs and/or degradation of mRNAs, leading to differential protein expression of
target genes. Based on a database that catalogues predicted polymorphisms in miRNA target sites (poly-miRTSs), we selected 568
polymorphisms within 3’-UTRs of target mRNAs and performed association analyses between these selected poly-miRTSs and
osteoporosis in 997 white subjects who were genotyped by Affymetrix Human Mapping 500K arrays. Initial discovery (in the 997
subjects) and replication (in 1728 white subjects) association analyses identified three poly-miRTSs (rs6854081, rs1048201, and
rs7683093) in the fibroblast growth factor 2 (FGF2) gene that were significantly associated with femoral neck bone mineral density
(BMD). These three poly-miRTSs serve as potential binding sites for 9 miRNAs (eg, miR-146a and miR-146b). Further gene expression
analyses demonstrated that the FGF2 gene was differentially expressed between subjects with high versus low BMD in three
independent sample sets. Our initial and replicate association studies and subsequent gene expression analyses support the conclusion
that these three polymorphisms of the FGF2 gene may contribute to susceptibility to osteoporosis, most likely through their effects on
altered binding affinity for specific miRNAs.  2011 American Society for Bone and Mineral Research.
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Introduction
O
steoporosis is a problem of excessive skeletal fragility
leading to large numbers of low-trauma fractures among
the elderly. Osteoporosis and its major risk factors, such as low
bone mineral density (BMD), are under strong genetic deter-
mination.
(1–3) The major goal ingenetic studies of osteoporosis is
to identify causal genetic variations underlying osteoporosis.
Genetic mutations that alter protein sequences and polymorph-
isms that regulate gene expression (ie, regulatory polymorph-
isms) are two naturally occurring genetic variations that are
identified and characterized often when studying the genetics
of complex diseases/traits.
(4,5)
MicroRNAs (miRNAs) are endogenous noncoding RNAs
containing 21 to 23 nucleotides that regulate posttranscriptional
gene expression, usually by binding to 3’-untranslated regions
(3’-UTRs) of target message RNAs (mRNAs).
(6,7) Therefore,
polymorphisms in 3’-UTRs of mRNAs potentially could alter
the affinity of miRNAs for their target mRNAs. This altered affinity
could affect the efficiency with which miRNAs regulate protein
expression by altering their capacity to repress mRNA translation
and/or promote mRNA decay. Regulatory polymorphisms in
miRNA target sites (poly-miRTSs) are being widely and actively
studied for their contribution to genetic variations in human
diseases ranging from Parkinson disease to cancer.
(8–12) Several
significant poly-miRTSs associated with cancers have been
identified
(8–11); for example, a significant association was found
between the risk of non–small cell lung cancer and a poly-
morphism in the let-7 miRNA complementary site in the 3’-UTR
of the KRAS gene.
(11) To date, however, genetic studies have not
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72been attempted to identify poly-miRTSs that may be associated
with osteoporosis risk.
Recently, a poly-miRTS database identified and catalogued
naturally occurring genome-wide DNA variations in putative
miRNA target sites.
(13) These predicted poly-miRTSs may affect
the regulation of target mRNA by miRNA and contribute to
phenotypic differences between individuals that alter the risk for
complex diseases such as osteoporosis. We selected a total of
568 poly-miRTSs that were genotyped recently using Affymetrix
Human Mapping 500K SNP arrays (Affymetrix, Santa Clara, CA,
USA) in a discovery sample of 997 unrelated white people and
performed association analyses to investigate the potential role
of these identified poly-miRTSs on osteoporosis. The initial
discovery and replication (in an independent sample 1,728 white
subjects) association studies (DNA level), along with subsequent
gene expression analyses (RNA level), identified three single-
nucleotide polymorphisms (SNPs) in the 3’-UTR of the fibroblast
growth factor 2 (FGF2) gene as putative binding sites for miRNAs
that may contribute to the risk of osteoporosis.
Materials and Methods
Samples
The study was approved by the necessary institutional review
board or research administration of the involved institutions.
Signed informed-consent documents were obtained from all
study participants before entering the study. Detailed char-
acteristics of studied subjects are summarized in Tables 1 and 4.
Association study samples
Initial discovery association sample
A total of 997 unrelated subjects (aged 50.3 18.3 years) were
identified from our established and ever-expanding database
containing more than 7000 subjects for the initial discovery
study. All identified subjects were US white people of European
origin living in the Midwestern United States in Omaha,
Nebraska. This sample was recruited with the aim of identifying
genes that influence the risk of various complex diseases (e.g.,
osteoporosis, obesity, and sarcopenia) and several important
complex traits by approaches such as genome-wide association
analyses.
(14–19) Strict exclusion criteria were adopted to minimize
any known potential confounding effects on bone phenotype
variations. Briefly, patients with chronic diseases/conditions that
potentiallymayaffectbone masswereexcluded. Thesediseases/
conditions included chronic disorders involving vital organs (eg,
heart, lung, liver, kidney, and brain), serious metabolic diseases
(eg, diabetes, hypo- or hyperparathyroidism, and hyperthyroid-
ism), other skeletal diseases (eg, Paget disease, osteogenesis
imperfecta, and rheumatoid arthritis), chronic use of drugs
affecting bone metabolism (eg, corticosteroid therapy and
anticonvulsant drugs), and malnutrition conditions (eg, chronic
diarrhea and chronic ulcerative colitis). Femoral neck (FN) bone
mineral density (BMD) was measured using Hologic densit-
ometers (Hologic, Inc., Bedford, MA, USA).
Replication association sample
This sample contained 1,728 unrelated white women (aged
51.6 12.9 years). All selected subjects were US white women of
European origin. All identified subjects were US white women of
EuropeanoriginlivinginthemidwesternUnitedStatesinOmaha
(Nebraska) and Kansas City (Missouri). This sample was recruited
with the aim to identify genes that influence the risk of various
complex diseases (eg, osteoporosis, obesity, and sarcopenia).
This sample was independent from the sample used in the initial
discovery association study.
Gene expression samples
Expression data for the FGF2 gene were obtained during studies
with three independent gene expression samples (Caucasians 1,
2, and 3 described below) with high versus low hip BMD. These
samples were recruited with an original purpose of systemically
searching for differentially expressed genes underlying BMD
variation (published data from the first sample
(20) and unpub-
lished data from the other two samples). The first sample
(Caucasian 1) consisted of 9 premenopausal white women. The
second sample (Caucasian 2) contained 40 unrelated white
women with high hip BMD and 40 matched white women with
low hip BMD. The third sample (Caucasian 3) consisted of 79
unrelated white women, including 39 with high and 40 with low
hipBMD. HipBMD valueisexpressed as Z-scorethatisdefinedas
the number of standard deviations of a BMD measurement
above (ie, a positive Z-score) or below (ie, a negative Z-score) the
age-, gender-, and ethnicity-matched population mean BMD. In
order to minimize any known potential confounding effects on
the variation in bone phenotype, these three samples were
recruited by adopting strict exclusion criteria that were similar to
those used to recruit the sample for the initial discovery
associationstudy.CirculatingmonocytesandBcellswereusedin
these gene expression studies because of their important role in
osteoclastogenesis. Circulating monocytes serve as progenitors
of osteoclasts
(20–23) and also produce a wide variety of factors
involved in bone metabolism, such as interleukin 1 (IL-1), tumor
necrosis factor a (TNF-a), IL-6, platelet-derived growth factor,
transforming growth factor b (TGF-b), and 1,25-dihydroxy-
vitamin D3 [1,25(OH)2D3].
(24,25) B cells may participate in oste-
oclastogenesis through expression of osteoclast-related factors,
such as RANKL, TGF-b, and osteoprotegerin (OPG).
(26)
Experimental procedures
DNA extraction and genotyping
Genomic DNA was extracted from whole human blood using a
commercial isolation kit (Gentra Systems, Minneapolis, MN, USA)






Age (years) 50.3 (18.3) 51.6 (12.9)
Height (cm) 170.8 (9.7) 163.3 (6.3)
Weight (kg) 80.2 (17.8) 71.4 (16.0)
Femoral neck BMD (g/cm
2) 0.814 (0.145) 0.793 (0.133)
Note: Data are shown as mean (SD).
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discovery association study were genotyped using Affymetrix
Human Mapping 500K arrays, which examined approximately
500,000 SNPs. Genotyping with the Affymetrix Mapping 250K
Nsp and Affymetrix Mapping 250K Sty arrays was performed at
the Vanderbilt Microarray Shared Resource at Vanderbilt
University MedicalCenter (Nashville,TN, USA) usingthe standard
protocol recommended by the manufacturer. Fluorescence
intensities were quantified using an Affymetrix Array Scanner
30007G. Dynamic model (DM)
(27) calls were used for quality
control of the genotyping experiment. Genotyping was
performed initially for 1000 US whites, and unsatisfactory arrays
were subject to regenotyping. Eventually, 997 subjects who had
at least one array (Nsp or Sty) reaching a 93% call rate were
retained. Subjects used in the replication association study were
genotyped using the Genome-Wide Human SNP Array 6.0
following the standardized procedures recommended by the
manufacturer.
Isolation of monocytes and B cells
A monocyte-negative isolation kit (Dynal Biotech, Inc., Lake
Success,NY,USA) wasusedtoisolatecirculatingmonocytesfrom
50mL of whole blood following the procedures recommended
by the manufacturer. B-cell isolation from 70mL of whole blood
was performed using a positive isolation method with
Dynabeads CD19 (Pan B) and DETACHaBEAD CD19 (Dynal
Biotech) following the manufacturer’s protocols.
Total RNA extraction and microarray assay
Total RNA was extracted from monocytes and B cells using a
Qiagen kit (Qiagen, Inc., Valencia, CA, USA) following the
procedures recommended by the manufacturer. Experimental
procedures for gene expression microarray assays were
performed according to the manufacturer’s protocol (Affyme-
trix). Briefly, RNA was converted to double-stranded cDNA. In
vitro transcription was performed to produce biotin-labeled
cRNA (BioArray HighYield RNA Transcription Labeling Kit, Enzo
Diagnostics, New York, NY, USA). Biotinylated cRNA was cleaned,
fragmented, and hybridized (Affymetrix Genechip Hybridization
Oven 640) to U133 A Gene Chips. Then microarrays were washed
(Affymetrix Fluidics Station 450), stained with phycoerythrin-
streptavidin, and scanned using an Affymetrix scanner (Gene
Array Scanner 3000).
Statistical analysis
GeneChip Operating Software (GCOS) was used to control
GeneChip fluidics stations and scanners (Affymetrix, Santa Clara,
CA, USA), acquire data, manage sample and experimental
information, and generate the raw array data in CEL files. We
used the Robust Multiarray Average (RMA) algorithm
(28) to
transform the probe-level raw data into gene expression data.
RMA can provide the most reproducible results and shows the
highest correlation coefficients with RT-PCR data among
currently available algorithms.
(29) Based on expression data
generated with the RMA algorithm, Student’s t test was used to
compare expression signals in subject groups with low versus
high BMD to identify differentially expressed genes.
Poly-miRTS identification and selection
The method of identifying and annotating poly-miRTS was
detailedbyBaoandcolleagues.
(13)Briefly,wefirstextractedSNPs
that are located in 3’-UTRs of all known human genes from
dbSNP build 126.
(30) Genomic locations for these SNPs then were
mapped onto mRNAs, and the criteria of TargetScanS
(31) were
used to predict miRNA target sites. About 22,000 human
predicted poly-miRTSs were collected from the poly-miRTS
database. Of these, 860 poly-miRTSs were genotyped using
Affymetrix 500K SNP arrays in the 997 unrelated white subjects.
Among the 860 genotyped poly-miRTSs, 292 were excluded
because of the following quality-control criteria: Allele frequency
deviated extremely from Hardy-Weinberg equilibrium (p<.001),
orminor allelefrequency (MAF)wasless than1%. Eventually, 568
poly-miRTSs were selected for subsequent association analyses.
Association analysis
Raw values were adjusted by four significant covariates (ie, age,
gender, height, and weight). PLINK (http://pngu.mgh.harvar-
d.edu/ purcell/plink/) performed linear regression analyses to
evaluate associations between the 568 selected poly-miRTSs and
femoral neck BMD. p values and regression coefficients (b value)
produced from linear regression analyses are two important
parameters for assessing associations.
SNP imputation and association testing
Since some of DNA samples for the original discovery study were
not available, it was not easy to retrospectively genotype, in
the initial discovery sample, the two interesting poly-miRTSs
(rs1048201 and rs7683093) that were genotyped in the repli-
cate study using Genome-Wide Human SNP Array 6.0 but were
not genotyped directly in the initial discovery sample using
Affymetrix Human Mapping 500K array. However, SNP imputa-
tion is a reasonable alternative method for inferring the ungeno-
typed SNPs. In order to perform association testing for these
two interesting poly-miRTSs, imputation was performed by
PLINK functions (http://pngu.mgh.harvard.edu/ purcell/plink/
pimputation.shtml) based on a reference panel from HapMap.
The process of SNP imputation and association testing included
the following: (1) finding flanking markers and haplotypes
(proxies) that are in strong linkage disequilibrium with the
reference SNPs and (2) testing these proxies for associations with
diseases within a haplotype-based framework.
Results
Association of poly-miRTS and osteoporosis
Thebasiccharacteristicsofassociationstudysubjectsarelistedin
Table 1. Weidentified7poly-miRTSs inourdiscovery sample that
manifested association signals with femoral neck BMD at the
significance level of p<.01; these 7 poly-miRTSs are potential
binding sites for 12 distinct miRNAs(eg, miR-146aand miR-146b)
(Table 2). The strongest association signal for femoral neck BMD
wasdetectedatpoly-miRTSrs1712intheF-boxprotein5(FBXO5)
gene (p¼2.54E-03); this poly-miRTS is located at a predicted
binding site for miR-549. In the replication study, with an
74 Journal of Bone and Mineral Research LEI ET AL.independent white sample, associations with femoral neck BMD
were replicated only for two of these SNPs (rs1712 and
rs6854081). However, the association direction for the regression
coefficient (b value) of rs1712 differed between the initial
discovery and replicate studies (Table 2). For rs6854081, a poly-
miRTS in the 3’-UTR of the FGF2 gene, the association direction
for the regression coefficient was the same in both the initial and
replicate studies, so our subsequent analyses focused on
rs6854081 in the FGF2 gene.
As shown in Fig. 1, subjects with a homozygous TT genotype
for rs6854081 had a higher raw femoral neck BMD than
individuals with a homozygous GG genotype. Fisher’s combined
p value
(32) from the two independent studies is more significant
(p¼4.18E-03) than the p values for each independent study
(Table 2). By searching the poly-miRTS database, we found two
additional poly-miRTSs (rs1048201 and rs7683093) in the FGF2
gene that were genotyped in the replicate study using Genome-
Wide Human SNP 6.0 Arrays but were not genotyped directly in
the initial discovery sample using Affymetrix Human Mapping
500K arrays. Therefore, we performed further association
analyses for these two SNPs in the replication sample and
found that both rs1048201 and rs7683093 were significantly
associated with femoral neck BMD in the replicate sample. We
also performed SNP imputation and association testing for these
two additional poly-miRTSs in the initial sample and found that
rs1048201, but not rs7683093, was significantly associated with
femoral neck BMD in the discovery sample. The three significant
SNPs (rs6854081, rs1048201, and rs7683093) reside within 9
predicted miRNA target sites (Table 3).
Gene expression of the FGF2 gene
To further investigate the relevance of the FGF2 gene to
osteoporosis and to provide complementary evidence support-
ing the associations detected earlier, we performed differential
expression analyses for the FGF2 gene in three distinct gene
expression studies (Table 4). These three studies compared FGF2
gene expression in subjects with high versus low BMD using two
distinct cell types related to bone metabolism (ie, B-lymphocytes
and monocytes). Two expression probes (204421_s_at and
204422_s_at) were specifically designed to detect expression of
the FGF2 gene in the Affymetrix Human Genome U133 A Array.
There was significant or nearly significant differential expression
in low versus high hip BMD for at least one of these probes in
each sample studied (Table 4). Moreover, in all three samples,
these probes consistently indicated decreased expression of the
FGF2 gene in the high versus low BMD groups.
Discussion
This study reports the important role of polymorphisms in 3’-
UTRs of mRNAs (miRNA-binding sites) in determining variations
inBMD. We have identified three significant poly-miRTSs that are
associated with BMD in the 3’-UTR of the FGF2 gene. These
findings are supported by three independent gene expression
analyses that consistently demonstrated depressed expression
of the FGF2 gene in subjects with high BMD compared with









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































POLYMORPHISMS AND OSTEOPOROSIS Journal of Bone and Mineral Research 75Fibroblast growth factor is well known for its functional effects
on bone biology. It plays a key role in the development of the
bone matrix and regulation of bone remodeling and has both
direct and indirect effects on osteoclast formation and bone
resorption.
(25,33,34) Specifically, fibroblast growth factor is
thought to stimulate osteoclast recruitment, development,
and bone pit resorption.
(25) Despite the functional importance
of FGF2 on bone, to the best of our knowledge, no previous
association studies have demonstrated a relationship between
polymorphisms of the FGF2 gene and bone phenotypes (eg,
BMD). In this study, we report, for the first time, that three
polymorphisms of the FGF2 gene are consistently associated
with BMD. The data from association analyses at the DNA level
and gene expression analyses at the RNA level are consistent in
supporting the concept that polymorphisms detected in the
FGF2 gene regulate BMD variation, possibly by altering the
affinity of mRNA products for specific miRNAs.
Based on the results from our association and expression
analyses, we would hypothesize the following potential
mechanismbywhichpoly-miRTSsregulateBMDthroughmiRNA.
Using rs6854081 as an example, miR-146a and miR-146b would
bind optimally to FGF2 mRNA transcripts containing allele T at
rs6854081. This optimal binding would be expected to
negatively regulate protein expression by promoting mRNA
degradation and/or repressing mRNA translation. Conversely,
binding ofthese miRNAs to mRNA transcripts with alleleG would
not be as strong and therefore would allow higher levels of
protein expression. Higher levels of FGF protein would be
expected to stimulate osteoclastogenesis through osteoclast
formation and late differentiation. This would enhance bone
resorption, leading to lower BMD, which is consistent with
findings of our gene expression studies; that is, high expression
of the FGF2 gene results in low BMD. Consequently, we can infer
that individuals with the TT genotype should have higher BMD
than subjects with the GG genotype, which is consistent with the
actual observation presented in Fig. 1. Extensive functional
studies will be required to confirm this proposed hypothetical
mechanism by which poly-miRTSs regulate BMD.
In the current initial discovery sample, we used multiple
approaches, described previously,
(35) to detect population
stratification that may lead to spurious association results. The
software Structure 2.2 (http://pritch.bsd.uchicago.edu/software.
html)analyzedupto10,000unlinkedmarkers andfound thatthe
vast majority (98%) of subjects were tightly clustered together.
The inflation factor l, calculated by Genomic Control,
(36) was
1.007, indicating that potential population stratification in this
Fig. 1. Distribution of raw femoral neck BMD stratified by rs6854081 genotypes in the discovery study.



















rs6854081 G/T 124036156 4088 T 0.131  0.020 8.37E-03 0.138  0.010 5.79E-02 GTTCTC miR-146a, miR-146b
rs1048201 T/C 124033757 1691 T 0.250 1.640 4.51E-02 0.178 0.009 4.68E-02 TGCTGA miR-545
rs7683093 C/G 124037534 5466 G 0.140 0.760 3.76 E-01 0.136  0.010 4.21E-02 TGCAAT miR-25, miR-32, miR-92,
miR-363, miR-367, miR-92b
aThe first allele represents the minor allele of each SNP.
bMAF¼minor allele frequency in the study sample.
cThelasttwopoly-miRTSs(rs1048201andrs7683093)werenotgenotypeddirectlyintheinitialdiscoverysampleusingAffymetrixHumanMapping500K
Arraysbutweregenotypeddirectlyin thereplicatestudyusingGenome-WideHumanSNPArray6.0. SNPimputation andassociationtestingforthesetwo
SNPs were performed by PLINK functions in the initial sample.
76 Journal of Bone and Mineral Research LEI ET AL.homogeneous US white population is very minimal. This
combined evidence suggests that the confounding effects from
population structure, if present, contribute very little toour initial
association results.
Among the identified poly-miRTSs collected in the data-
base,
(13) only 568 poly-miRTSs were assessed for potential
associations with osteoporosis in this study. Most of the poly-
miRTSs ( 22,000) identified in the database were not covered
by either the Affymetrix Human Mapping 500K Array or the
Genome-Wide Human SNP Array 6.0. Consequently, there is an
obvious need for better coverage of SNPs in 3’-UTRs in future
commercial SNP arrays. As the technology advances, further
studies will be needed to evaluate how osteoporosis is affected
by the SNPs that were included in the poly-miRTS database
(13)
but were not analyzed in this study. These future studies should
provide additional insights into the importance of polymorph-
isms in 3’-UTRs of mRNAs on regulation of gene expression as it
relates to bone biology.
Examining the role of miRNAs in regulating bone represents a
new frontier in bone biology that we are just beginning to
explore.Thisstudyis,tothebestofourknowledge,thefirsteffort
to examine the role of miRNA target-site polymorphisms in
regulating bone, and these initial findings may be of significant
interest to the bone community. The results presented represent
an initial logical step toward understanding whether miRNA
target-site polymorphisms play a role in bone remodeling. In the
future, extensive efforts will be required to fully disclose the
underlying biologic mechanisms for the associations between
the predicted poly-miRTSs and bone phenotypes. These efforts
may include the following: (1) Correlations between genotypes
of poly-miRTSs and expression of the FGF2 gene at mRNA and
protein levels should be established in a large sample, with the
purpose of gaining an understanding of the potentially different
effects that poly-miRTSs may have on regulating expression of
the FGF2 in vivo. (2) Tests should be conducted to determine if
specific miRNAs actually regulate expression of the FGF2 gene by
binding to predicted target sequences. Luciferase reporter
assays would be a very good method for achieving this goal
(detailed in ref. 12). By constructing allele-specific Renilla
luciferase plasmids containing one of the alleles of the poly-
miRTS, this method also can test the allele-specific effects of
miRNA on regulating expression of FGF2. (3) Polymorphisms in
3’-UTRs of mRNAs potentially could alter the affinity of miRNAs
for target mRNAs, and this altered affinity could affect the
efficiency with which miRNAs regulate protein expression by
promoting mRNA decay and/or by repressing mRNA translation.
Therefore, it is necessary to determine whether poly-miRTSs
have different effects on regulating mRNA degradation of the
FGF2 gene by measuring mRNA half-life via quantitative RT-PCR
analyses. Should all the preceding proposed analyses be
confirmed, a conclusion about how poly-miRTSs regulate
variation of bone phenotypes will be made with high confidence
and resolution.
Inconclusion,wehavedetectedseveralputativeosteoporosis-
associated poly-miRTSs in this study. Although we have not
specifically determined the biologic mechanisms underlying
these associations, our results should be of interest to the bone
community because the detected polymorphisms might be
worthy candidates for future functional studies. It is anticipated
that future large-scale genome-wide scans for poly-miRTSs and
follow-up functional experiments will identify additional poly-
miRTSs involved in the pathogenesis of osteoporosis and the
specificmechanismsbywhichtheyexerttheirbiologicinfluence.
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